Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface.

Transcription mediated by hypoxia-inducible factor (HIF-1) contributes to tumor angiogenesis and metastasis but is also involved in activation of cell-death pathways and normal physiological processes. Given the complexity of HIF-1 signaling, it could be advantageous to target a subset of HIF-1 effectors rather than the entire pathway. We compare the genome-wide effects of three molecules that each interfere with the HIF-1-DNA interaction: a polyamide targeted to the hypoxia response element, small interfering RNA targeted to HIF-1alpha, and echinomycin, a DNA-binding natural product with a similar but less specific sequence preference than the polyamide. The polyamide affects a subset of hypoxia-induced genes consistent with its binding site preferences. For comparison, HIF-1alpha siRNA and echinomycin each affect the expression of nearly every gene induced by hypoxia. Remarkably, the total number of genes affected by either polyamide or HIF-1alpha siRNA over a range of thresholds is comparable. The data show that polyamides can be used to affect a subset of a pathway regulated by a transcription factor. In addition, this study offers a unique comparison of three complementary approaches towards exogenous control of endogenous gene expression.

[1]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[2]  P. Dervan,et al.  Shape selective recognition of T.A base pairs by hairpin polyamides containing N-terminal 3-methoxy (and 3-chloro) thiophene residues. , 2003, Bioorganic & medicinal chemistry.

[3]  A. Monks,et al.  Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. , 2005, Cancer research.

[4]  P. Dervan,et al.  Design of a sequence-specific DNA bisintercalator. , 2004, Angewandte Chemie.

[5]  M. Van Dyke,et al.  Echinomycin binding sites on DNA. , 1984, Science.

[6]  N. Ferrara,et al.  Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.

[7]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[8]  P. Dervan,et al.  Allosteric inhibition of protein--DNA complexes by polyamide--intercalator conjugates. , 2003, Journal of the American Chemical Society.

[9]  Peter B. Dervan,et al.  Recognition of the four Watson–Crick base pairs in the DNA minor groove by synthetic ligands , 1998, Nature.

[10]  M. Waring,et al.  Echinomycin: a bifunctional intercalating antibiotic , 1974, Nature.

[11]  S. Israels,et al.  BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF , 2003, Oncogene.

[12]  S. Kourembanas,et al.  Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. , 1995, Circulation research.

[13]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[14]  G. Semenza,et al.  Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.

[15]  P. Dervan,et al.  Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide , 2007, Proceedings of the National Academy of Sciences.

[16]  D. Rees,et al.  Structural basis for G•C recognition in the DNA minor groove , 1998, Nature Structural Biology.

[17]  M. Waring,et al.  Echinomycin inhibits chromosomal DNA replication and embryonic development in vertebrates. , 2004, Nucleic acids research.

[18]  G. Semenza,et al.  Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. , 1994, The Journal of biological chemistry.

[19]  T. Tuschl,et al.  Mechanisms of gene silencing by double-stranded RNA , 2004, Nature.

[20]  R. Sakakibara,et al.  Identification and characterization of the hypoxia-responsive element of the human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene. , 2004, Journal of biochemistry.

[21]  Pilar Blancafort,et al.  Designing Transcription Factor Architectures for Drug Discovery , 2004, Molecular Pharmacology.

[22]  B. Brüne,et al.  Tumor hypoxia and cancer progression. , 2006, Cancer letters.

[23]  L. del Peso,et al.  Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. , 2005, The Biochemical journal.

[24]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[25]  Evidence that a minor groove-binding peptide and a major groove-binding protein can simultaneously occupy a common site on DNA. , 1992, Biochemistry.

[26]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[27]  J. Trauger,et al.  Footprinting methods for analysis of pyrrole-imidazole polyamide/DNA complexes. , 2001, Methods in enzymology.

[28]  P. Ratcliffe,et al.  The prolyl hydroxylase enzymes that act as oxygen sensors regulating destruction of hypoxia-inducible factor alpha. , 2004, Advances in enzyme regulation.

[29]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[30]  G. Semenza,et al.  HIF-1 and human disease: one highly involved factor. , 2000, Genes & development.

[31]  J. Schalken,et al.  Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. , 2004, Oncogene.

[32]  Richard G. Jenner,et al.  Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Livingston,et al.  Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. , 2004, Cancer cell.

[34]  C C Case,et al.  Regulation of an Endogenous Locus Using a Panel of Designed Zinc Finger Proteins Targeted to Accessible Chromatin Regions , 2001, The Journal of Biological Chemistry.

[35]  P. Dervan,et al.  Recognition of the DNA minor groove by pyrrole-imidazole polyamides. , 2003, Current opinion in structural biology.

[36]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[37]  R. Motzer,et al.  Renal-cell carcinoma. , 1996, The New England journal of medicine.

[38]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[39]  Masahiro Hiraoka,et al.  Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element , 2006, Acta oncologica.

[40]  O. Iliopoulos,et al.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. , 2004, Molecular cancer research : MCR.

[41]  K. Webster,et al.  Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. , 1998, Biochemical and biophysical research communications.

[42]  P. Dervan,et al.  Improved nuclear localization of DNA-binding polyamides , 2006, Nucleic acids research.

[43]  G. Melillo,et al.  Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy , 2006, Molecular Cancer Research.

[44]  R. Beerli,et al.  Engineering polydactyl zinc-finger transcription factors , 2002, Nature Biotechnology.

[45]  J. L. Rosa,et al.  6-Phosphofructo-2-kinase (pfkfb3) Gene Promoter Contains Hypoxia-inducible Factor-1 Binding Sites Necessary for Transactivation in Response to Hypoxia* , 2004, Journal of Biological Chemistry.

[46]  C. Mello,et al.  Revealing the world of RNA interference , 2004, Nature.

[47]  G. Hannon,et al.  Unlocking the potential of the human genome with RNA interference , 2004, Nature.

[48]  D J Segal,et al.  Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Waring,et al.  Sequence-specific binding of echinomycin to DNA: evidence for conformational changes affecting flanking sequences. , 1984, Nucleic acids research.

[50]  B. Leyland-Jones,et al.  Echinomycin: The first bifunctional intercalating agent in clinical trials , 2004, Investigational New Drugs.

[51]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.

[52]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[53]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[54]  J. Trauger,et al.  Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Klco,et al.  Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Dervan,et al.  Solid-phase synthesis of DNA binding polyamides on oxime resin. , 2002, Bioorganic & medicinal chemistry.